Loading company…
RadioNano Therapeutics develops targeted radiation treatments for cancer.
RadioNano Therapeutics develops boron neutron capture therapy (BNCT), which uses a reaction between thermal neutrons and boron to target cancer cells. Its RN-501 product is a hydrophilic boron-containing inorganic nanoparticle. Founded in 2024, it is based in Tokyo and is at Series A stage. In September 2024, it raised JPY 450 million from Kyoto University Innovation Capital, Mitsubishi UFJ Capital, DBJ Capital and Japan Science and Technology Agency to advance RN-501 toward clinical trials and expand its cancer treatment pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in